Revolution Medicines exec sells 15,448 shares
Revolution Medicines, Inc. (RVMD) reported that Chief Global Commercialization Officer Anthony Mancini exercised options and sold shares on September 10, 2026 under a pre-arranged Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Revolution Medicines, Inc. (RVMD) reported that Chief Global Commercialization Officer Anthony Mancini exercised options and sold shares on September 10, 2026 under a pre-arranged Rule 10b5-1 trading plan. He exercised 9,363 stock options at an exercise price of $33.62 per share, acquiring the same number of common shares, and sold an aggregate of 15,448 common shares in multiple trades at weighted-average prices around $203–$207 per share. Following the option exercise, he held 96,746 stock options and his equity position also includes 43,700 restricted stock units, which are subject to time-based vesting through April 2029.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Mancini Anthony
Role
See Remarks
Sold
15,448 shs ($3.15M)
Approx. gross sale proceeds
$3.15M
Approx. exercise cost
$315K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F8 | 9,363 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 9,363 | $33.62 | $315K |
| Sale | Common Stock F1, F2 | 6,019 | $203.2844 | $1.22M |
| Sale | Common Stock F1, F3 | 5,530 | $204.1357 | $1.13M |
| Sale | Common Stock F1, F4 | 2,420 | $205.0513 | $496K |
| Sale | Common Stock F1, F5 | 1,179 | $206.0995 | $243K |
| Sale | Common Stock F1, F6, F7 | 300 | $207.1733 | $62K |
Holdings After Transaction:
Stock Option (Right to Buy) — 96,746 contracts (Direct);
Common Stock — 43,890 shares (Direct)
Footnotes (8)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
- F2. The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4. The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5. The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6. The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7. Includes 43,700 restricted stock units.
- F8. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Key Figures
Options exercised: 9,363 shares
Option exercise price: $33.62 per share
Shares sold: 15,448 shares
+5 more
8 metrics
Options exercised
9,363 shares
Stock options on common stock exercised on September 10, 2026
Option exercise price
$33.62 per share
Exercise price for 9,363 stock options
Shares sold
15,448 shares
Total RVMD common shares sold on September 10, 2026
Sale price range
$202.64–$207.28 per share
Price ranges across multiple sale transactions
Weighted-average sale price example
$203.28 per share
One reported weighted-average price for a 6,019-share sale tranche
Options remaining
96,746 options
Stock options on RVMD common stock held after the reported exercise
Restricted stock units
43,700 units
Restricted stock units included in the insider’s equity holdings
Option expiration date
March 31, 2035
Expiration date for the exercised option grant
Key Terms
Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, vesting commencement date, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 43,700 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price reported in Column 4 above reflects the weighted average sale price."
vesting commencement date financial
"measured from April 1, 2025 (the "Vesting Commencement Date") and one"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did RVMD’s Chief Global Commercialization Officer report on this Form 4?
The officer reported exercising 9,363 stock options at $33.62 per share and selling 15,448 common shares on September 10, 2026 in multiple trades at weighted-average prices of about $203–$207 per share, all under a Rule 10b5-1 trading plan.
How many RVMD options did Anthony Mancini exercise and at what price?
Anthony Mancini exercised 9,363 stock options for Revolution Medicines, Inc. common stock at an exercise price of $33.62 per share on September 10, 2026, converting them into 9,363 shares of common stock.
Were the RVMD insider transactions made under a Rule 10b5-1 trading plan?
Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026, indicating they were pre-arranged rather than discretionary trades based on new information.
What RVMD equity awards and options does the insider hold after these transactions?
After exercising options, he held 96,746 stock options on RVMD common stock. A separate footnote states his holdings include 43,700 restricted stock units, which vest over time based on continued service through each vesting date.
What is the vesting schedule of the RVMD stock options exercised in this Form 4?
The option vests 25% of the total shares on the first anniversary of April 1, 2025, with the remaining shares vesting in equal monthly installments over the following three years, so that it becomes fully vested and exercisable by the fourth anniversary, subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
